InvestorsHub Logo
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: vinmantoo post# 2089

Thursday, 11/18/2021 8:25:25 PM

Thursday, November 18, 2021 8:25:25 PM

Post# of 3015

Do you think ENTA will advance EDP-514 in trials in combination with a nuc, at least for now?

They already completed a phase-1b combination trial of EDP-514 with a nuc (the trial that enrolled “viremic” patients) without any problems, so I presume they will advance the combination to phase-2.

I sure hope ENTA has other [than RNA-destabilizer] HepB targets in mind.

That’s a good bet; Jay Luly has spoken of multiple (undisclosed) HBV mechanisms in the discovery phase. What’s needed is something that is highly active against the sub-viral particles responsible for emitting HBsAg.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News